Physician profile
Marcy K Deemedio
NPI 1548351828
$680.52
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical School (Registered Nurse) provider received nationally (typical 2025 total: $120).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $421 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.25 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $106.18 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $105.91 | 2024 | |
| Biomarin Pharmaceutical INC. | $82.94 | 2024 | Voxzogo 1.2mg |
| Dexcom, INC. | $68.17 | 2023-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $60.42 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eton Pharmaceuticals, INC. | $44.94 | 2023-2024 | Alkindi |
| Novo Nordisk INC | $32.27 | 2023 | Norditropin |
| Medtronic, INC. | $32.17 | 2023-2025 | Minimed 780g |
| Neurocrine Biosciences, INC. | $26.04 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.14 | 2023 | Gvoke Hypopen |
| Chiesi USA, INC. | $20.59 | 2024 | Myalept |
| Abbott Laboratories | $20.10 | 2024 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $19.41 | 2024 | |
| Beta Bionics, INC. | $18.68 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $18.56 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Deemedio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.